EUVIMEDEUVIMED entdecken
Crossref

Novel SGLT2 inhibitors with endothelial-protective potential: a combined computational and experimental approach

Jarritt Romanik, Nina Gardella, Gabriela Dematteo, Yiru Zhao, Timothy Moy, Asher Brandt, Zhao Li iD

Journal of Basic and Clinical Physiology and Pharmacology · 21.07.2026 · 37 (4) · 305-314

DOI: 10.1515/jbcpp-2025-0147 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, online erschienen am 14.05.2026. Verfasst von Jarritt Romanik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Department of Chemistry, University of Saint Joseph, West Hartford, CT, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents, Endothelial Cells, Endothelium, Vascular. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of anti-diabetic drugs with cardiovascular benefits independent of glycemic control, partly via endothelial protection. Identifying novel inhibitors with both high affinity and vascular-protective effects remains a priority.

Methods

Structure-based high-throughput virtual screening (HTVS) of 14 million ligands was performed using Schrödinger Glide. Compounds with better docking scores than empagliflozin (−13.615) were filtered for ADME properties using QikProp. Ten lead compounds were evaluated in human coronary artery endothelial cells under diabetic and ischemia-reperfusion (I/R) models. Assays included glucose uptake, cytotoxicity (LDH), oxidative stress (ROS), and nitrosative stress (NO).

Results

Compound #7 demonstrated the most potent activity, reducing glucose uptake by 55 % (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsEndothelial CellsEndothelium, VascularHumansOxidative StressSodium-Glucose Transporter 2Molecular Docking SimulationGlucoseReactive Oxygen SpeciesBenzhydryl CompoundsHigh-Throughput Screening AssaysNitrosative StressGlucosides

Stichwörter der Autor:innen

ADME profilingSGLT2 inhibitorscardiovascular complicationsendothelial protectiontype 2 diabetes mellitusvirtual screening

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2GlucoseSLC5A2 protein, humanReactive Oxygen SpeciesBenzhydryl CompoundsempagliflozinGlucosides

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences and Department of Chemistry, University of Saint Joseph, West Hartford, CT, USA.

ORCID-Profile: Zhao Li

Zitieren

APA

Romanik, J., Gardella, N., Dematteo, G., Zhao, Y., Moy, T., Brandt, A., & Li, Z. (2026). Novel SGLT2 inhibitors with endothelial-protective potential: a combined computational and experimental approach. Journal of Basic and Clinical Physiology and Pharmacology, 37(4), 305-314. https://doi.org/10.1515/jbcpp-2025-0147

Vancouver

Romanik J, Gardella N, Dematteo G, Zhao Y, Moy T, Brandt A, et al. Novel SGLT2 inhibitors with endothelial-protective potential: a combined computational and experimental approach. Journal of Basic and Clinical Physiology and Pharmacology. 2026;37(4):305-314. doi:10.1515/jbcpp-2025-0147

BibTeX
@article{Romanik2026,
  author = {Romanik, Jarritt and Gardella, Nina and Dematteo, Gabriela and Zhao, Yiru and Moy, Timothy and Brandt, Asher and Li, Zhao},
  title = {Novel SGLT2 inhibitors with endothelial-protective potential: a combined computational and experimental approach},
  journal = {Journal of Basic and Clinical Physiology and Pharmacology},
  year = {2026},
  volume = {37},
  number = {4},
  pages = {305--314},
  doi = {10.1515/jbcpp-2025-0147}
}
Kostenlos starten →